Women with estrogen receptor (ER)-positive early breast cancer who received 5 years of endocrine therapy had a persistent risk of recurrence of and death from breast cancer for at least 20 years after diagnosis, highlighting the long-term risk of recurrence in patients with this breast cancer subtype [13]. The gene discussed is ESR1; the disease is breast carcinoma.